Cargando…

SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Marx, Nikolaus, Müller-Wieland, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290867/ https://www.ncbi.nlm.nih.gov/pubmed/37287082 http://dx.doi.org/10.1093/eurheartj/ehad282

Ejemplares similares

Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study
por: Blanco, Christopher Antonio, et al.
Publicado: (2023)

Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2023)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
por: Tamez-Perez, Héctor Eloy, et al.
Publicado: (2017)

Current Utilization Trends of SGLT-2 Inhibitors in Type 2 Diabetics With Heart Failure
por: Dhillon, Puneet, et al.
Publicado: (2021)

A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
por: Liu, Allen Yan Lun, et al.
Publicado: (2022)

Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience
por: Tabella, Erika, et al.
Publicado: (2023)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
por: Ryan, Patrick B., et al.
Publicado: (2018)

SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
por: Keller, Daria M., et al.
Publicado: (2022)

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
por: Jeong, Su Jin, et al.
Publicado: (2021)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
por: Theofilis, Panagiotis, et al.
Publicado: (2023)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
por: Oh, Chang-Myung, et al.
Publicado: (2019)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
por: Voorrips, Suzanne N., et al.
Publicado: (2022)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021–2022: an analysis of real-world data
por: Alonso, Alvaro, et al.
Publicado: (2023)

Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure
por: Correale, Michele, et al.
Publicado: (2021)

Efficacy and safety of SGLT2 inhibitors in patients with heart failure: A protocol for systematic review and meta-analysis
por: Wang, Li, et al.
Publicado: (2022)

Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
por: Chow, Erica, et al.
Publicado: (2023)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
por: Hwang, In-Chang, et al.
Publicado: (2020)

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
por: Lam, Carolyn S. P., et al.
Publicado: (2019)

SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
por: Pabel, Steffen, et al.
Publicado: (2021)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
por: Tsampasian, Vasiliki, et al.
Publicado: (2021)

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
por: Heath, Rebecca, et al.
Publicado: (2022)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021)

SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
por: Sung, Jasper, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_drs49csd3u8ro75ieq5va0q0s0